BioTuesdays

Category - Markets

Fusion
Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022
Markets

Brookline starts IceCure at buy; PT $5.65

Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...

February 2, 2022
Markets

Stifel starts Vigil Neuroscience at buy; PT $24

Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...

February 1, 2022
ViewRay Logo
Markets

Stifel starts ViewRay at buy; PT $7

Stifel initiated coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and price target of $7, reflecting a multiple of 8.3 times estimated 2023 revenue of $130-million. The stock closed at $4.46 on Jan. 24. “We see...

January 25, 2022
BioCardia
Markets

Dawson James ups BioCardia to buy; PT $4

Dawson James upgraded BioCardia (NASDAQ:BCDA) to “buy” with a $4 price target, citing multiple clinical programs in heart failure and a business deal potential. The stock closed at $1.39 on Jan. 21. Analyst Jason...

January 24, 2022
acutus logo
Markets

BTIG cuts Acutus Medical to neutral from buy

BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...

January 20, 2022